FNDR-20123
Product Specifications
UNSPSC Description
FNDR-20123 is a safe, first-in-class, and orally active anti-malarial HDAC inhibitor with IC50s of 31 nM and 3 nM for Plasmodium and human HDAC, respectively. FNDR-20123 exerts anti-malarial activity against Plasmodium falciparum asexual stage (IC50=41 nM) and sexual blood stage (IC50=190 nM for male gametocytes). FNDR-20123 inhibits HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (IC50=25/29/2/11/282 nM, respectively.) and inhibits Class III HDAC isoforms at nanomolar concentrations[1].
Target Antigen
HDAC; Parasite
Type
Reference compound
Related Pathways
Anti-infection;Cell Cycle/DNA Damage;Epigenetics
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/fndr-20123.html
Purity
98.08
Solubility
DMSO : 31.25 mg/mL (ultrasonic)
Smiles
O=C(NO)C1=CC=C(CN2N=NC(C3=CC=C(CN4CCCC4)C=C3)=C2)C=C1.[H]Cl
Molecular Weight
413.90
References & Citations
[1]Potluri V, et al. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria. Malar J. 2020;19(1):365. Published 2020 Oct 12.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-131708A/FNDR-20123-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-131708A/FNDR-20123-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2641930-61-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
